

A multicentre study using the chemotherapy combination of bi-monthly Xeloda and Eloxatin, with the addition of Avastin, in patients with advanced colorectal cancer

Submission date 01/05/2006	Recruitment status No longer recruiting	☒ Prospectively registered ☐ Protocol
Registration date 15/05/2006	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 02/06/2015	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Michael Findlay

Contact details

Cancer Trials New Zealand (CTNZ)
Rm 3443 Building 503
Faculty of Medical and Health Sciences
University of Auckland
Private Bag 92019
Auckland
New Zealand
1003
+64 (0)9 373 7599 ext 82005
mp.findlay@auckland.ac.nz

Additional identifiers

Protocol serial number

CTNZ_05_6

Study information

Scientific Title

A multicentre study using the chemotherapy combination of bi-monthly Xeloda and Eloxatin, with the addition of Avastin, in patients with advanced colorectal cancer

Acronym

XEN study

Study objectives

Bi-monthly dose intensified capecitabine (Xeloda) and oxaliplatin (Eloxatin) with concurrent bevacizumab (Avastin) will be a tolerable, effective, drug combination in the treatment of advanced colorectal cancer.

Ethics approval required

Old ethics approval format

Ethics approval(s)

New Zealand Multi-Regional Ethics Committee, 20/04/2006, ref: MEC/06/04/041

Primary study design

Interventional

Study design

Multi-centre phase IV study

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Advanced colorectal cancer

Interventions

Dose intensified capecitabine days 1-7, oxaliplatin IV day 1 (diCapeOx), repeat every 14 days plus concurrent bevacizumab IV day 1, repeat every 14 days. Treatment will continue until progression, unacceptable toxicity or patient request.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Capecitabine (Xeloda), oxaliplatin (Eloxatin), bevacizumab (Avastin)

Primary outcome(s)

Progression free survival

Key secondary outcome(s)

1. Proportion of patients who receive at least 75% of the planned dose
2. Rate of grade 3 and 4 neutropenia
3. Grade 3 and 4 toxicity rates
4. Tumour response rates
5. Survival

Completion date

31/03/2009

Eligibility

Key inclusion criteria

1. Histological/cytological confirmation of colorectal cancer
2. Locally recurrent or metastatic disease
3. Patient performance status (Eastern Cooperative Oncology Group (ECOG) 0-1
4. Creatinine clearance greater than or equal to 50 ml/min assessed by Cockcroft-Gault formula. If Cockcroft-Gault formula yields less than 50 ml/min, direct measurement of creatinine clearance or glomerular filtration rate may be made according to local practice. Direct measurement must be greater than 50 ml/min.
5. Urine dipstick of proteinuria <2+. Patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline, should undergo a 24-hour urine collection and must demonstrate ≤1 g of protein per 24 hr
6. Laboratory values as follows:
Haematology:
 - a. Absolute neutrophil count (ANC) $>1.5 \times 10^9 /l$
 - b. Platelet count $>100 \times 10^9 /l$
 - c. Haemoglobin $>9 \text{ g/dl}$ (may be transfused to maintain or exceed this level)
 - d. International normalized ratio (INR) <1.5 ; arterial pulse propagation time (APPT) $<1.5 \times$ upper limit of normal (ULN)Biochemistry:
 - a. Total bilirubin $<1.5 \times$ ULN; serum total bilirubin $<30 \mu\text{mol/l}$
 - b. Aspartate aminotransferase (AST) or alanine transaminase (ALT) $<2.5 \times$ ULN in patients without liver metastases; $<5 \times$ ULN in patients with liver metastases
 - c. Serum creatinine $<2.0 \text{ mg/dl}$ or $177 \mu\text{mol/l}$ (see creatinine clearance criteria above)
7. Age ≥ 18 years
8. Accessible for treatment and follow up
9. Written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

1. Previous systemic therapy (excluding adjuvant treatment) for advanced colorectal cancer
2. Less than six months following last dose of adjuvant systemic therapy
3. Current or recent (within the 30 days prior to starting study treatment) treatment of another investigational drug or participation in another investigational drug study
4. Unsuitable for treatment with capecitabine (e.g. fluorouracil [5FU] side effects suggestive of dihydropyrimidine dehydrogenase deficiency; gastrointestinal [GI] disease precluding oral therapy)
5. Serious uncontrolled infection
6. Unsuitable for treatment with oxaliplatin (e.g. significant neuropathy i.e. greater than grade 1 Common Toxicity Criteria [CTC] criteria)
7. Brain and/or leptomeningeal disease
8. Pregnant or breastfeeding women
9. Concurrent anticancer therapy (any radiation must be completed at least four weeks before registration)
10. Other malignancy in previous five years except adequately treated basal cell or squamous cell carcinoma of skin or in-situ carcinoma of the cervix
11. Treatment with antiviral agent sorivudine, or related compounds such as brivudine
12. Clinically significant and active cerebral vascular disease and/or cerebral vascular accident ≤ 6 months prior to registration, myocardial infarction ≤ 1 year prior to registration, uncontrollable hypertension whilst receiving chronic medication, unstable angina, New York Heart Association (NYHA) grade 2 or greater congestive heart failure or serious cardiac arrhythmia requiring medication
13. Major surgery within 28 days prior to treatment commencement or anticipation of the need for major surgical procedure during the course of the study
14. Current or recent (within 10 days prior to study treatment start) use of full-dose oral or parenteral anticoagulants for therapeutic purposes
15. Chronic daily treatment with aspirin (>325 mg/day)
16. Serious, non-healing wound, ulcer, or bone fracture
17. Evidence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or patient at high risk from treatment complications
18. Patients with known allergy to Chinese hamster ovary cell proteins or other recombinant human or humanized antibodies or to any excipients of bevacizumab formulation or to any other study drugs
19. Patients unable to swallow oral tablets

Date of first enrolment

26/05/2006

Date of final enrolment

31/03/2009

Locations

Countries of recruitment

New Zealand

Study participating centre
Cancer Trials New Zealand (CTNZ)
Auckland
New Zealand
1003

Sponsor information

Organisation
Cancer Trials New Zealand (CTNZ)

Funder(s)

Funder type
Industry

Funder Name
Research grant from Roche Products (NZ) Ltd

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	02/10/2014		Yes	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes